NEXENTIS TECHNOLOGIES INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $844.87 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2025-11-13
- NEXENTIS TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $24.14.
- NEXENTIS TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.45.
- NEXENTIS TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2019 was $0.45.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-09-30 | $844.87 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $24.14 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $24.14 10-Q · filed 2025-05-15 | |||
| 2020-09-30 | $0.45 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $0.45 10-Q · filed 2020-08-11 | |||
| 2020-03-31 | $0.45 10-Q · filed 2020-05-15 | |||
| 2019-12-31 | $0.45 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |